Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma

NCT06574698 · clinicaltrials.gov ↗

RECRUITING

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Neuroblastoma
GD2 Antibody (Naxitamab)

Interventions

DRUG: Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy

Sponsor

Guangzhou Women and Children's Medical Center